Targeting Oxidative Stress in Chronic Beryllium Disease

针对慢性铍病的氧化应激

基本信息

  • 批准号:
    7749333
  • 负责人:
  • 金额:
    $ 33.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-07-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The overall goal of this application is to understand the role of oxidative stress as a potential target in the pathogenesis of chronic beryllium disease (CBD). CBD is an inflammatory hypersensitivity lung disease that occurs in over 800,000 beryllium-exposed workers in the US characterized by pulmonary granulomas. The molecular mechanisms by which beryllium regulates the chronic production of lung inflammation and granuloma formation are unknown. We hypothesize that beryllium induces oxidative stress by altering thiol homeostasis which enhances beryllium specific T cells to produce excessive Th1 cytokines and proliferate, two key features of CBD pathophysiology. Three specific aims are proposed to address the hypothesis. Specific aim 1 will examine the mechanisms by which beryllium stimulates oxidative stress in beryllium specific CD4+ T cells by altering thiol redox status. Specific aim 2 will determine whether beryllium-mediated oxidative stress alters the balance between histone acetyltransferase (HAT) and histone deacetyltransferase (HDAC) activities that modulates inflammation and steroid sensitivity in CBD. This aim will test whether beryllium exposure creates oxidative stress that impairs HDAC activity as a mechanism that amplifies inflammation in CBD. Specific aim 3 will examine the potential therapeutic effect of a 5 aminosalicylic acid in CBD subjects. This last aim will assess a novel new therapy in CBD patients that targets beryllium-mediated oxidative stress and inflammation. The proposed experiments elucidate novel mechanisms that explain the excessive cytokine response to beryllium and pinpoint the role of antioxidant imbalance in CBD and mechanistic approaches to treat CBD. PUBLIC HEALTH RELEVANCE: CBD is a granulomatous lung disease that occurs in a large population of US workers exposed to beryllium. The proposed study focuses on novel findings that beryllium is both an antigen and initiator of oxidative stress that results in alterations in cellular thiol status. The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects.
描述(由申请人提供):本申请的总体目标是了解氧化应激作为慢性铍病(CBD)发病机制中潜在目标的作用。 CBD 是一种炎症性超敏性肺部疾病,在美国有超过 800,000 名接触铍的工人发生,其特征是肺肉芽肿。铍调节肺部炎症和肉芽肿形成的慢性产生的分子机制尚不清楚。我们假设铍通过改变硫醇稳态来诱导氧化应激,从而增强铍特异性 T 细胞产生过量的 Th1 细胞因子并增殖,这是 CBD 病理生理学的两个关键特征。提出了三个具体目标来解决这一假设。具体目标 1 将研究铍通过改变硫醇氧化还原状态刺激铍特异性 CD4+ T 细胞氧化应激的机制。具体目标 2 将确定铍介导的氧化应激是否会改变组蛋白乙酰转移酶 (HAT) 和组蛋白脱乙酰转移酶 (HDAC) 活性之间的平衡,从而调节 CBD 中的炎症和类固醇敏感性。这一目标将测试铍暴露是否会产生氧化应激,从而损害 HDAC 活性,作为放大 CBD 炎症的机制。具体目标 3 将检查 5 个氨基水杨酸对 CBD 受试者的潜在治疗效果。最后一个目标将评估一种针对 CBD 患者的新型疗法,该疗法针对铍介导的氧化应激和炎症。拟议的实验阐明了新的机制,解释了对铍的过度细胞因子反应,并查明了 CBD 中抗氧化剂失衡的作用以及治疗 CBD 的机制方法。公共卫生相关性:CBD 是一种肉芽肿性肺部疾病,发生在大量接触铍的美国工人中。拟议的研究重点关注铍既是抗原又是氧化应激引发剂的新发现,氧化应激会导致细胞硫醇状态的改变。这些研究将通过在 CBD 受试者中使用 5 个氨基水杨酸的新型治疗方法从机制上针对这些变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian J Day其他文献

Nebulized Thiocyanate Dramatically Improves Lung Infection Outcomes in Mice
  • DOI:
    10.1016/j.freeradbiomed.2012.10.244
  • 发表时间:
    2012-11-01
  • 期刊:
  • 影响因子:
  • 作者:
    Joshua D Chandler;Elysia Min;Jie Huang;David P Nichols;Brian J Day
  • 通讯作者:
    Brian J Day

Brian J Day的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian J Day', 18)}}的其他基金

Selenocyanate as a novel treatment of cystic fibrosis lung disease
硒氰酸盐作为囊性纤维化肺病的新型治疗方法
  • 批准号:
    10312798
  • 财政年份:
    2019
  • 资助金额:
    $ 33.64万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    10626938
  • 财政年份:
    2018
  • 资助金额:
    $ 33.64万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    10434637
  • 财政年份:
    2018
  • 资助金额:
    $ 33.64万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    9769732
  • 财政年份:
    2018
  • 资助金额:
    $ 33.64万
  • 项目类别:
Optimization of AEOL10150 treatment of sulfur mustard-induced lung toxidrome in a pig model
AEOL10150 治疗猪芥子气肺中毒模型的优化
  • 批准号:
    9938593
  • 财政年份:
    2018
  • 资助金额:
    $ 33.64万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8450168
  • 财政年份:
    2009
  • 资助金额:
    $ 33.64万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8053472
  • 财政年份:
    2009
  • 资助金额:
    $ 33.64万
  • 项目类别:
Targeting Oxidative Stress in Chronic Beryllium Disease
针对慢性铍病的氧化应激
  • 批准号:
    8246509
  • 财政年份:
    2009
  • 资助金额:
    $ 33.64万
  • 项目类别:
Adaptive glutathione responses to cigarette smoke in COPD
慢性阻塞性肺病患者对香烟烟雾的适应性谷胱甘肽反应
  • 批准号:
    7383987
  • 财政年份:
    2007
  • 资助金额:
    $ 33.64万
  • 项目类别:
Adaptive glutathione responses to cigarette smoke in COPD
慢性阻塞性肺病患者对香烟烟雾的适应性谷胱甘肽反应
  • 批准号:
    7535245
  • 财政年份:
    2007
  • 资助金额:
    $ 33.64万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 33.64万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了